Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.58 |
| ▸ | PARP1 | P09874 | 6/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 3/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11906514 | 0.87 | PARP10 (0.56) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL28724506 | 0.84 | CLK4 (0.51) | MKNK1GSK3B | |
| SCHEMBL25085727 | 0.80 | PARP10 (0.52) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL2027837 | 0.80 | PARP10 (0.63) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL17797707 | 0.79 | GSK3B (0.51) | PARP10PARP11MKNK1GSK3BGRM5 | |
| SCHEMBL3008897 | 0.77 | ROCK2 (0.51) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL3008902 | 0.77 | ROCK2 (0.51) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL20894239 | 0.76 | PARP10 (0.58) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL29631237 | 0.76 | PARP10 (0.58) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL14395011 | 0.75 | PARP10 (0.61) | PARP10PARP1F7F3PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | claimed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, PF4 | PARP10 41/4885PARP1 21/4885F7 58/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | PARP10 32/4885PARP1 19/4885F7 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.